scorecardresearch
Add as a preferred source on Google
Tuesday, September 30, 2025
TopicCDSCO

Topic: CDSCO

Why apex ophthalmologists’ body wants to review new eye drops designed to replace reading glasses

All India Ophthalmological Society has set up expert group to review PresVu & develop guidelines on side-effects, keeping in mind 'potential inappropriate marketing, indiscriminate use'.

34 more fixed dose combination drugs likely to be banned, apex regulator says after big crackdown

A total of 344 such medicines were banned in 2018, and another 156, used for common conditions such as fever, allergies, hypertension, colds etc, earlier this month.

Blockbuster diabetes & obesity drug gets nod for India launch but may be available only next year

Tirzepatide is a type 2 diabetes and obesity drug sold by US firm Eli Lilly under the brand names Mounjaro and Zepbound. It may take around 6 months for it to be launched in India.

Drug regulator’s plan to bring all nicotine replacement therapies under prescription gets ICMR nod

Doctors & experts are divided on the move's efficacy. Some believe this could help ensure responsible use, while others feel it could reduce access for those benefiting from it.

Drug regulator CDSCO asks all medical device makers to ‘self-report adverse events’ to mitigate risks

CDSCO says Centre’s programme to identify such risks has been in place since 2015, but till now only hospitals designated as monitoring centres would report such events on voluntary basis.

Central regulator to now give NOC for export of new, unapproved medicines after safety concerns

India’s exports of pharmaceuticals during 2022-23 was valued at $25.4 billion with a growth of almost 3.25 percent over the previous financial year, according to Pharmexcil.

Drug regulator tightens sampling norms to test quality of medicines & cosmetics reaching market

CDSCO last week notified streamlined guidelines on sampling, conceded that at present sampled drugs are mostly from big brands and urban areas. 

After prohibiting popular FDC for kids under 4, drug regulator scrutinises other cold & cough remedies

Following December notice prohibiting combination of chlorpheniramine maleate & phenylephrine hydrochloride, CDSCO has ‘decided to rope in paediatricians to review other permitted FDCs’.

Indian pharma firms now liable to recall defective drugs as Modi govt notifies new norms

Under revised good manufacturing practices (GMP) norms, pharma companies will be required to assume onus for quality of drugs to ensure they do not place patients at risk.

Global pharma majors pitch for faster approval of innovative drugs in India but CDSCO remains cautious

Organisation of Pharmaceutical Producers of India seeks nod for drugs to be marketed at same time as US, Europe. But regulator rarely permits a drug launch without local clinical trials.

On Camera

Jana Sangh leader VK Malhotra brought Advani to Delhi, kept the party afloat after 1984 setback

Unlike his colleagues from the time of the BJS, several of whom became governors and held other constitutional posts, Malhotra chose to lead a quiet and simple retired life after the massive 2014 victory of the BJP.

Market regulator SEBI clears Adani Group of impropriety alleged by Hindenburg Research

SEBI probe concluded that purported loans and fund transfers were paid back in full and did not amount to deceptive market practices or unreported related party transactions.

In Nepal, young dreams of serving in Indian Army crash as Agnipath halts a centuries-old tradition

Since 1815, Nepali Gorkhas have served in Indian & British Armies, as well as in Bihar, Bengal & Assam Police. Since Agnipath scheme came in, no Nepal-domiciled Gorkha has enlisted.

Something’s hidden in the Oval Office photo of Trump, Munir, Sharif. India must look closely

What Munir has achieved with Trump is a return to normal, ironing out the post-Abbottabad crease. The White House picture gives us insight into how Pakistan survives, occasionally thrives and thinks.